AtaiBeckley (formerly ATAI Life Sciences)
↗Berlin, Germany (original); U.S. redomiciliation completed December 30, 2025
AtaiBeckley is a clinical-stage biopharmaceutical company formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited in November 2025. Founded in 2018 by Christian Angermayer, the company is dedicated to developing innovative psychedelic-based neuroplastogens and related therapeutics to treat mental health disorders including treatment-resistant depression, social anxiety disorder, and other psychiatric conditions. The company operates at the intersection of psychedelic science and neuropharmacology, with a mission to transform patient outcomes through rapid-acting, convenient mental health treatments that address significant unmet medical needs in psychiatry where traditional therapies have failed.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Psychedelic therapeutics, Psychiatric mental health
SIZE & FINANCIALS
Employees:51-200
Revenue:$2.3M (TTM as of November 2025)
Founded:2018
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$522.1M (private rounds)
Investors:Peter Thiel, Thiel Capital, Hercules Capital, GrayBella Capital
STOCK
Exchange:NASDAQ
Ticker:ATAI
Market Cap:$1.47B
PIPELINE
Stage:Phase 2
Lead Drug Stage:BPL-003: Phase 2b/3-ready
Modalities:Psychedelics, Intranasal spray, Oral transmucosal film, Oral tablet, 5-HT2AR agonists, Non-hallucinogenic psychedelics
Active Trials:3
Trial Phases:Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Beckley Psytech Limited (merged November 2025), Recognify Life Sciences (22.4% stake), Compass Pathways (22.4% stake)
Key Partnerships:Beckley Psytech Limited (strategic combination completed November 2025), Psilera Inc. (DMT patent licensing agreement 2025), IntelGenx Corp. (acquired for VLS-01 manufacturing capabilities), Recognify Life Sciences (cognitive impairment programs)
COMPETITION
Position:Leader
Competitors:Compass Pathways (NASDAQ: CMPS), MindMed/Mind Medicine (NASDAQ: MNMD), Cybin Inc., Tryp Therapeutics, Psilera Inc., Perception Neuroscience Holdings
LEADERSHIP
Key Executives:
Srinivas Rao, M.D., Ph.D. - Chief Executive Officer
Kevin Craig, M.D. - Chief Medical Officer
Glenn Short, Ph.D. - Chief Scientific Officer
Gerd Kochendoerfer, Ph.D. - Chief Operating Officer
Scientific Founders:Christian Angermayer (Founder/Chairman), Cosmo Feilding Mellen (Beckley Psytech CEO/Co-Founder)
Board Members:Christian Angermayer (Chairman), Scott Braunstein, M.D. (Vice Chairman, Lead Independent Director), Laurent Fischer, M.D., Cosmo Feilding Mellen (Beckley Psytech representative), Robert Hershberg, M.D., Ph.D. (Beckley Psytech representative)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AtaiBeckley (formerly ATAI Life Sciences). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.